Meeting
2017 ASCO Annual Meeting
A phase II randomized, multicentric clinical trail comparing recombinant human endostatin plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locally advanced low-risk nasopharyngeal carcinoma.
Authors
Min Kang
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
Min Kang , Shaomin Lin , Haisheng Zhu , Sihui Liao , Haixin Huang , Bin Yu , Hongqian Wang , Meilian Liu , Jinxian Zhu , Guang Huang , Yutao Qin , Zhuxin Wei , Qinghua Du , Kai Hu , Tingting Zhang , Pingting Zhou , Xueyin Liao , Rensheng Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02237924
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6063)
DOI
10.1200/JCO.2017.35.15_suppl.6063
Abstract #
6063
Poster Bd #
51
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Recombinant human endostatin combined with intensity-modulated radiotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A phase II, randomized, multicenter clinical trial.
First Author: Min Kang
Poster
2021 ASCO Annual Meeting
Endostar combined with intensity-modulated radiotherapy in low-risk local advanced nasopharyngeal carcinoma: A phase II, randomized, multicentric clinical trial.
First Author: Min Kang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prospective evaluation of dose-escalated preoperative concurrent chemo-radiation with image-guided intensity modulated radiation therapy in locally advanced rectal cancers.
First Author: Raunaq Puri